

Ref: FOI/GS/ID 6448

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

14 May 2021

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to antiretroviral therapies.

*You asked:*

*Q1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:*

- a. Juluca (rilpivirine/dolutegravir)*
- b. Dovato (lamivudine/dolutegravir)*
- c. Triumeq (abacavir/lamivudine/dolutegravir)*
- d. Tivicay (dolutegravir)*
- e. Isentress (raltegravir)*
- f. Biktarvy (TAF/emtricitabine/bictegravir)*
- g. Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)*
- h. Symtuza (TAF/emtricitabine/darunavir/cobisistat)*
- i. Odefsey (TAF/emtricitabine/rilpivirine)*
- j. Descovy (TAF/emtricitabine)*
- k. Truvada or generic TDF/emtricitabine*

*Q2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):*

- a. for the latest 6-month period*
- b. for the 6 months from July-December 2019*

*Q3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for?*

- a. HIV treatment*
- b. Pre-exposure prophylaxis (PrEP)*

*Q4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for?*

- a. HIV treatment*
- b. Pre-exposure prophylaxis (PrEP)*

Trust response:

1. For the six month time period Apr-Sep 2020

a. 0

b. 0

c. 19

d. 48

e. 52

f. 2

g. 4

h. 4

i. 11

j. 34

k. 117

2.

a. 215

b. 200

3. 179 (we do not have the data to split indication or branded/generic)

4. 608 (we do not have the data to split indication or branded/generic)